GeoVax Labs, Inc. New - GOVX STOCK NEWS

GeoVax Labs has entered an exclusive license agreement with PNP Therapeutics for Gedeptin®, aimed at treating advanced head and neck cancers. The deal grants GeoVax rights to key intellectual property and clinical materials. Gedeptin has shown promise in early trials, demonstrating safety and tumor reduction in patients with solid tumors. The ongoing Phase 1/2 trial for recurrent head and neck squamous cell carcinoma is funded by the FDA, which has also granted Gedeptin orphan drug status, providing regulatory incentives.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced that Chairman & CEO David Dodd will present at the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. Mr. Dodd’s presentation will be available for on-demand listening starting at 7:00 AM ET on September 13, 2021. The conference will allow participants to register and view the presentation online. GeoVax is a biotechnology firm dedicated to developing vaccines for infectious diseases and cancer, utilizing a unique MVA-VLP based platform to stimulate robust immune responses.

GeoVax Labs, Inc. (Nasdaq: GOVX) presented data at the ESMED General Assembly regarding their COVID-19 vaccine candidate, GEO-CM02, which aims to provide broader immunity against evolving SARS-CoV-2 variants. Utilizing the GV-MVA-VLP™ platform, the vaccine targets multiple proteins to potentially reduce immune escape risks. Dr. Mark J. Newman highlighted positive efficacy results from animal studies, indicating that the vaccine induces functional antibodies and T-cell responses. GeoVax envisions its vaccine as a key component in future coronavirus vaccination strategies.

GeoVax Labs, Inc. (Nasdaq: GOVX) announced its participation in the SNN Network Summer Virtual Event 2021 on August 18, 2021, at 12:30 PM EST. CEO David Dodd will present and address investor queries during the session. The event offers a chance for one-on-one meetings with the company through secure video conferencing. GeoVax specializes in developing vaccines against infectious diseases and cancers, using a unique MVA-VLP based platform. The company is focused on ongoing vaccine programs for COVID-19, HIV, and other critical diseases.

GeoVax Labs, Inc. (GOVX) announced its Q2 2021 financial results, reporting a net loss of $1,314,033 ($0.21 per share), compared to a loss of $455,204 ($0.66 per share) in Q2 2020. The increase in losses is attributed to higher R&D and administrative expenses, particularly related to their COVID-19 vaccine program. As of June 30, 2021, cash balances increased to $19.5 million, bolstered by stock sales and warrant exercises. The company continues to advance its COVID-19 vaccine and cancer immunotherapy programs, supported by an SBIR grant and collaborations.

GeoVax Labs, Inc. (GOVX) will report its second quarter 2021 financial results on August 11, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will review financial results and corporate updates. Participants can pre-register for the call and will receive dial-in details. GeoVax is focused on developing vaccines against infectious diseases and cancer using its patented MVA-VLP platform, with ongoing programs for COVID-19, HIV, and more.

GeoVax Labs announced a significant breakthrough in vaccine development with its MVA-SUDV-VLP vaccine, achieving 100% protection against the Sudan Ebolavirus (SUDV) in preclinical studies. This innovative vaccine, which only requires a single dose, was presented at the American Society for Virology's annual meeting. The vaccine’s efficacy was demonstrated in guinea pigs, showing that it can protect against a lethal challenge of SUDV. GeoVax aims to advance this vaccine to non-human primate testing, further establishing its platform's ability to combat infectious diseases.

GeoVax Labs (Nasdaq: GOVX) announced the issuance of U.S. Patent No. 11,052,148 for a vaccine targeting the Hepatitis B virus, addressing an unmet therapeutic need for over 250 million people globally. This patent supports a modified vaccinia Ankara (MVA) vector designed to generate an immune response, applicable for both prevention and treatment of chronic HBV infections. The patent arises from a collaboration with Georgia State University. The company focuses on developing human immunotherapies and vaccines for infectious diseases and cancer.

GeoVax Labs, a biotechnology firm focused on human immunotherapies and vaccines, announced participation in the Alliance Global Partners’ Virtual Healthcare Symposium on June 17, 2021. The management team will conduct 1-on-1 investor meetings during the event. GeoVax's development programs target vaccines for COVID-19, Zika, Ebola, HIV, and various cancers, utilizing an innovative MVA-VLP platform that stimulates robust immune responses akin to natural infections. For meeting requests, contact AGP Events at agpevents@allianceg.com.